Contact Information: CONTACT: Michael Brennan Chairman Email: Telephone: (805) 557-0614
Micro Imaging Technology, Inc. Retains Taglich Brothers, Inc. for Research and Analytical Coverage
| Source: Micro Imaging Technology, Inc.
SAN CLEMENTE, CA--(Marketwire - July 1, 2008) - Micro Imaging Technology, Inc. (OTCBB : MMTC ), the supplier of a patented non-biological based system which can
currently identify up to 23 species of bacteria in a matter of minutes at a
cost of pennies per test, announced that it has retained Taglich Brothers,
Inc. to provide research, analytical coverage and quarterly updates on the
Company.
Taglich Brothers, Inc. (member NASD, SIPC) is a full service broker dealer
focused exclusively on microcap companies, which is defined as companies
with less than $250 million in market capitalization. Taglich Brothers
currently offers institutional and retail brokerage services, investment
banking and comprehensive research to the investment community. More
information on Taglich Brothers, including a recent research report on the
Company, can be found by visiting www.taglichbrothers.com or by calling
(646) 290-5960.
Michael Brennan, Chairman of Micro Imaging Technology, Inc., stated, "Our
Company is extremely pleased to have retained the services of such a high
quality firm. The capabilities of Taglich Brothers will enhance the
information stream provided to our shareholders and the investment
community." Mr. Brennan further stated, "As the Company continues to grow,
we are striving to provide a broader base of information for our investors
and shareholders through a variety of independent research firms."
About Micro Imaging Technology:
The Company has developed and patented a technology for rapid microbe
detection and identification. The MIT 1000 System measures scattered light
intensity as individual microbes pass through a laser beam. The intensity
pattern of the scattered light is a direct consequence of the size, shape
and external and internal optical characteristics of the microbe. The MIT
System is non-biological and does not rely on biological agents,
conventional chemical processing, fluorescent tags, gas chromatography or
DNA analysis.
MIT has demonstrated the ability to detect and identify, within several
minutes, the microbes Escherichia coli, Listeria, Salmonella,
Staphylococcus aureus, and other pathogenic bacteria. MIT recently
performed over 300 tests for the identification the aforementioned
contaminants and scored 95% accuracy. The System can currently identify 23
species of bacteria and is easily expandable. The identification process
has been verified by North American Science Associates, Inc. (NAMSA), an
independent, internationally recognized biological testing laboratory. The
NAMSA Test Report, in the Company's opinion, demonstrated the accuracy,
speed and efficiency of the MIT System over conventional processes and is
available from the Company. www.micro-imaging.com
This release contains statements that are forward-looking in nature.
Statements that are predictive in nature, that depend upon or refer to
future events or conditions or that include words such as "expects,"
"anticipates," "intends," "plans," "believes," "estimates," and similar
expressions are forward-looking statements. These statements are made
based upon information available to the Company as of the date of this
release, and we assume no obligation to update any such forward-looking
statements. These statements are not guarantees of future performance and
actual results could differ materially from our current expectations.
Factors that could cause or contribute to such differences include, but are
not limited to dependence on suppliers; short product life cycles and
reductions in unit selling prices; delays in development or shipment of new
products; lack of market acceptance of our new products or services;
inability to continue to develop competitive new products and services on a
timely basis; introduction of new products or services by major
competitors; our ability to attract and retain qualified employees;
inability to expand our operations to support increased growth; and
declining economic conditions, including a recession. These and other
factors and risks associated with our business are discussed from time to
time within our filings with the Securities and Exchange Commission.